Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-6916 · 1 trial · 1 indication
Blood samples will be collected to determine the AUC0-inf of MK-6916.
Blood samples will be collected to determine the AUC0-24 of MK-6916.
Blood samples will be collected to determine the C24 of MK-6916.
Blood samples will be collected to determine the C12 of MK-6916.
Blood samples will be collected to determine the Cmax of MK-6916.
Blood samples will be collected to determine the Tmax of MK-6916.
Blood samples will be collected to determine the CL/F of MK-6916.
Blood samples will be collected to determine the Vz/F of MK-6916.
Blood samples will be collected to determine the t1/2 of MK-6916.
| Arm | Type | Description |
|---|---|---|
| MK-6916 + Diltiazem | EXPERIMENTAL | Participants will receive MK-6916 and diltiazem orally. |
| Name | Type | Description |
|---|---|---|
| MK-6916 | DRUG | Oral administration |
| Diltiazem | DRUG | Oral administration |
Inclusion Criteria: The key inclusion criteria include but are not limited to the following: * Has a body-mass index (BMI) 18 to 32 kg/m\^2 Exclusion Criteria: The key exclusion criteria include but are not limited to the following: * Has a history of clinically significant endocrine, gastroint...
MK-6916 is an investigational small molecule being studied in healthy participants. It is currently in Phase 1 clinical development, and the available trial focuses on evaluating its plasma levels when given with multiple doses of diltiazem. MK-6916 is not approved for any condition and remains under investigation.
MK-6916 is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company is conducting clinical trials to evaluate the drug's pharmacokinetics in healthy participants.
MK-6916 is in Phase 1 clinical development. The single completed trial, NCT06818968, was a Phase 1 study in healthy participants. MK-6916 is investigational and has not been approved by regulatory authorities.
MK-6916 has one completed Phase 1 trial, NCT06818968, titled "A Study of the Effect of Multiple Doses of Diltiazem on the Plasma Levels of MK-6916 in Healthy Participants (MK-6916-005)." The study enrolled 37 healthy adults in the United States and was uncontrolled, meaning it did not use a comparator group.
No, MK-6916 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The completed trial in healthy participants was designed to assess how diltiazem affects MK-6916 plasma levels, not to establish safety or efficacy for a specific disease.